 | • レポートコード：B-GIR08C4299 • 出版社/出版日：GlobalInfoResearch / 2019年8月 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、122ページ • 納品方法：Eメール • 産業分類：Medical Devices & Consumables |
| Single User | ￥522,000 (USD3,480) | ▷ お問い合わせ |
| Corporate User | ￥1,044,000 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査レポートは、PARP（ポリADPリボースポリメラーゼ）阻害剤の世界市場について調べ、まとめました。種類別セグメントは、リンパルザ、ゼジュラ、ルブラカ、タルツェナ、その他等、用途別セグメントは、卵巣がん、乳がん、その他等に区分しました。PARP（ポリADPリボースポリメラーゼ）阻害剤の世界市場概観、企業動向、企業別PARP（ポリADPリボースポリメラーゼ）阻害剤シェア、市場規模推移、市場規模予測（2019年-2024年）、主要地域分析（北米、ヨーロッパ、アジア等）、主要国分析（日本、中国、アメリカ等）データなどの情報が含まれています。 ・PARP（ポリADPリボースポリメラーゼ）阻害剤の市場概観 ・PARP（ポリADPリボースポリメラーゼ）阻害剤の企業概要（事業概要、製品種類、販売量、価格、売上、市場シェア等） ・PARP（ポリADPリボースポリメラーゼ）阻害剤の企業別販売動向、市場シェア、市場集中度、競争動向 ・PARP（ポリADPリボースポリメラーゼ）阻害剤の世界市場規模 ・PARP（ポリADPリボースポリメラーゼ）阻害剤の北米市場分析（アメリカ、カナダ、メキシコ等） ・PARP（ポリADPリボースポリメラーゼ）阻害剤のアメリカ市場規模推移 ・PARP（ポリADPリボースポリメラーゼ）阻害剤のカナダ市場規模推移 ・PARP（ポリADPリボースポリメラーゼ）阻害剤のメキシコ市場規模推移 ・PARP（ポリADPリボースポリメラーゼ）阻害剤のヨーロッパ市場分析（ドイツ、イギリス、ロシア、フランス、イタリア等） ・PARP（ポリADPリボースポリメラーゼ）阻害剤のドイツ市場規模推移 ・PARP（ポリADPリボースポリメラーゼ）阻害剤のイギリス市場規模推移 ・PARP（ポリADPリボースポリメラーゼ）阻害剤のロシア市場規模推移 ・PARP（ポリADPリボースポリメラーゼ）阻害剤のアジア太平洋市場分析（日本、中国、韓国、インド、東南アジア等） ・PARP（ポリADPリボースポリメラーゼ）阻害剤の日本市場規模推移 ・PARP（ポリADPリボースポリメラーゼ）阻害剤の中国市場規模推移 ・PARP（ポリADPリボースポリメラーゼ）阻害剤の韓国市場規模推移 ・PARP（ポリADPリボースポリメラーゼ）阻害剤のインド市場規模推移 ・PARP（ポリADPリボースポリメラーゼ）阻害剤の東南アジア市場規模推移 ・PARP（ポリADPリボースポリメラーゼ）阻害剤の南米市場分析（ブラジル、アルゼンチン等） ・PARP（ポリADPリボースポリメラーゼ）阻害剤の中東・アフリカ市場分析（サウジアラビア、UAE、南アフリカ等） ・PARP（ポリADPリボースポリメラーゼ）阻害剤の種類別分析/販売量、売上、市場シェア（リンパルザ、ゼジュラ、ルブラカ、タルツェナ、その他） ・PARP（ポリADPリボースポリメラーゼ）阻害剤の用途別分析/市場規模（卵巣がん、乳がん、その他） ・PARP（ポリADPリボースポリメラーゼ）阻害剤の市場予測2019年-2024年（地域別予測、種類別予測、用途別予測） ・PARP（ポリADPリボースポリメラーゼ）阻害剤の販売チャネル・代理店・貿易業者・ディーラー分析 |
PARP inhibitors are a group of pharmacological inhibitors of the enzyme poly ADP ribose polymerase (PARP).
They are developed for multiple indications; the most important is the treatment of cancer. Several forms of cancer are more dependent on PARP than regular cells, making PARP an attractive target for cancer therapy. PARP inhibitors appear to improve progression-free survival in women with recurrent platinum-sensitive ovarian cancer, as evidenced mainly by olaparib added to conventional treatment.
Scope of the Report:
PARP (Poly ADP-Ribose Polymerase) Inhibitor first approval in United States in 2014. And in the last several years, global market (value) of PARP (Poly ADP-Ribose Polymerase) Inhibitor developed rapidly, with an average growth rate of 133.8% during 2015 to 2018.
The classification of PARP (Poly ADP-Ribose Polymerase) Inhibitor includes Lynparza, Zejula, Rubraca, Talzenna and other. Lynparza (olaparib) is a first-in-class PARP inhibitor and the first targeted treatment to potentially exploit DNA damage response (DDR) pathway deficiencies, such as BRCA mutations, to preferentially kill cancer cells.
The worldwide market for PARP (Poly ADP-Ribose Polymerase) Inhibitor is expected to grow at a CAGR of roughly 31.4% over the next five years, will reach 4855 million US$ in 2024, from 1239.9 million US$ in 2019, according to a new GIR (Global Info Research) study.
This report focuses on the PARP (Poly ADP-Ribose Polymerase) Inhibitor in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
Market Segment by Manufacturers, this report covers
AstraZeneca
Tesaro
Merck & Co
Clovis Oncology
Pfizer
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Lynparza
Zejula
Rubraca
Talzenna
Other
Market Segment by Applications, can be divided into
Ovarian Cancer
Breast Cancer
Other
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe PARP (Poly ADP-Ribose Polymerase) Inhibitor product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of PARP (Poly ADP-Ribose Polymerase) Inhibitor, with price, sales, revenue and global market share of PARP (Poly ADP-Ribose Polymerase) Inhibitor in 2017 and 2018.
Chapter 3, the PARP (Poly ADP-Ribose Polymerase) Inhibitor competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the PARP (Poly ADP-Ribose Polymerase) Inhibitor breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2014 to 2019.
Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2014 to 2019.
Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2014 to 2019.
Chapter 12, PARP (Poly ADP-Ribose Polymerase) Inhibitor market forecast, by regions, type and application, with sales and revenue, from 2019 to 2024.
Chapter 13, 14 and 15, to describe PARP (Poly ADP-Ribose Polymerase) Inhibitor sales channel, distributors, customers, research findings and conclusion, appendix and data source.
Table of Contents
1 Market Overview
1.1 PARP (Poly ADP-Ribose Polymerase) Inhibitor Introduction
1.2 Market Analysis by Type
1.2.1 Lynparza
1.2.2 Zejula
1.2.3 Rubraca
1.2.4 Talzenna
1.2.5 Other
1.3 Market Analysis by Applications
1.3.1 Ovarian Cancer
1.3.2 Breast Cancer
1.3.3 Other
1.4 Market Analysis by Regions
1.4.1 North America (United States, Canada and Mexico)
1.4.1.1 United States Market States and Outlook (2014-2024)
1.4.1.2 Canada Market States and Outlook (2014-2024)
1.4.1.3 Mexico Market States and Outlook (2014-2024)
1.4.2 Europe (Germany, France, UK, Russia and Italy)
1.4.2.1 Germany Market States and Outlook (2014-2024)
1.4.2.2 France Market States and Outlook (2014-2024)
1.4.2.3 UK Market States and Outlook (2014-2024)
1.4.2.4 Russia Market States and Outlook (2014-2024)
1.4.2.5 Italy Market States and Outlook (2014-2024)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
1.4.3.1 China Market States and Outlook (2014-2024)
1.4.3.2 Japan Market States and Outlook (2014-2024)
1.4.3.3 Korea Market States and Outlook (2014-2024)
1.4.3.4 India Market States and Outlook (2014-2024)
1.4.3.5 Southeast Asia Market States and Outlook (2014-2024)
1.4.4 South America, Middle East and Africa
1.4.4.1 Brazil Market States and Outlook (2014-2024)
1.4.4.2 Egypt Market States and Outlook (2014-2024)
1.4.4.3 Saudi Arabia Market States and Outlook (2014-2024)
1.4.4.4 South Africa Market States and Outlook (2014-2024)
1.4.4.5 Turkey Market States and Outlook (2014-2024)
1.5 Market Dynamics
1.5.1 Market Opportunities
1.5.2 Market Risk
1.5.3 Market Driving Force
2 Manufacturers Profiles
2.1 AstraZeneca
2.1.1 Business Overview
2.1.2 PARP (Poly ADP-Ribose Polymerase) Inhibitor Type and Applications
2.1.2.1 Product A
2.1.2.2 Product B
2.1.3 AstraZeneca PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
2.2 Tesaro
2.2.1 Business Overview
2.2.2 PARP (Poly ADP-Ribose Polymerase) Inhibitor Type and Applications
2.2.2.1 Product A
2.2.2.2 Product B
2.2.3 Tesaro PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
2.3 Merck & Co
2.3.1 Business Overview
2.3.2 PARP (Poly ADP-Ribose Polymerase) Inhibitor Type and Applications
2.3.2.1 Product A
2.3.2.2 Product B
2.3.3 Merck & Co PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
2.4 Clovis Oncology
2.4.1 Business Overview
2.4.2 PARP (Poly ADP-Ribose Polymerase) Inhibitor Type and Applications
2.4.2.1 Product A
2.4.2.2 Product B
2.4.3 Clovis Oncology PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
2.5 Pfizer
2.5.1 Business Overview
2.5.2 PARP (Poly ADP-Ribose Polymerase) Inhibitor Type and Applications
2.5.2.1 Product A
2.5.2.2 Product B
2.5.3 Pfizer PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
3 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales, Revenue, Market Share and Competition by Manufacturer (2017-2018)
3.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales and Market Share by Manufacturer (2017-2018)
3.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue and Market Share by Manufacturer (2017-2018)
3.3 Market Concentration Rate
3.3.1 Top 3 PARP (Poly ADP-Ribose Polymerase) Inhibitor Manufacturer Market Share in 2018
3.3.2 Top 6 PARP (Poly ADP-Ribose Polymerase) Inhibitor Manufacturer Market Share in 2018
3.4 Market Competition Trend
4 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Analysis by Regions
4.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales, Revenue and Market Share by Regions
4.1.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales and Market Share by Regions (2014-2019)
4.1.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue and Market Share by Regions (2014-2019)
4.2 North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales and Growth Rate (2014-2019)
4.3 Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales and Growth Rate (2014-2019)
4.4 Asia-Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales and Growth Rate (2014-2019)
4.5 South America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales and Growth Rate (2014-2019)
4.6 Middle East and Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales and Growth Rate (2014-2019)
5 North America PARP (Poly ADP-Ribose Polymerase) Inhibitor by Country
5.1 North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales, Revenue and Market Share by Country
5.1.1 North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales and Market Share by Country (2014-2019)
5.1.2 North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue and Market Share by Country (2014-2019)
5.2 United States PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales and Growth Rate (2014-2019)
5.3 Canada PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales and Growth Rate (2014-2019)
5.4 Mexico PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales and Growth Rate (2014-2019)
6 Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor by Country
6.1 Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales, Revenue and Market Share by Country
6.1.1 Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales and Market Share by Country (2014-2019)
6.1.2 Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue and Market Share by Country (2014-2019)
6.2 Germany PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales and Growth Rate (2014-2019)
6.3 UK PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales and Growth Rate (2014-2019)
6.4 France PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales and Growth Rate (2014-2019)
6.5 Russia PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales and Growth Rate (2014-2019)
6.6 Italy PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales and Growth Rate (2014-2019)
7 Asia-Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor by Country
7.1 Asia-Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales, Revenue and Market Share by Country
7.1.1 Asia-Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales and Market Share by Country (2014-2019)
7.1.2 Asia-Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue and Market Share by Country (2014-2019)
7.2 China PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales and Growth Rate (2014-2019)
7.3 Japan PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales and Growth Rate (2014-2019)
7.4 Korea PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales and Growth Rate (2014-2019)
7.5 India PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales and Growth Rate (2014-2019)
7.6 Southeast Asia PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales and Growth Rate (2014-2019)
8 South America PARP (Poly ADP-Ribose Polymerase) Inhibitor by Country
8.1 South America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales, Revenue and Market Share by Country
8.1.1 South America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales and Market Share by Country (2014-2019)
8.1.2 South America PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue and Market Share by Country (2014-2019)
8.2 Brazil PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales and Growth Rate (2014-2019)
8.3 Argentina PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales and Growth Rate (2014-2019)
8.4 Colombia PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales and Growth Rate (2014-2019)
9 Middle East and Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor by Countries
9.1 Middle East and Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales, Revenue and Market Share by Country
9.1.1 Middle East and Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales and Market Share by Country (2014-2019)
9.1.2 Middle East and Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue and Market Share by Country (2014-2019)
9.2 Saudi Arabia PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales and Growth Rate (2014-2019)
9.3 Turkey PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales and Growth Rate (2014-2019)
9.4 Egypt PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales and Growth Rate (2014-2019)
9.5 Nigeria PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales and Growth Rate (2014-2019)
9.6 South Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales and Growth Rate (2014-2019)
10 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Segment by Type
10.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales, Revenue and Market Share by Type (2014-2019)
10.1.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales and Market Share by Type (2014-2019)
10.1.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue and Market Share by Type (2014-2019)
10.2 Lynparza Sales Growth and Price
10.2.1 Global Lynparza Sales Growth (2014-2019)
10.2.2 Global Lynparza Price (2014-2019)
10.3 Zejula Sales Growth and Price
10.3.1 Global Zejula Sales Growth (2014-2019)
10.3.2 Global Zejula Price (2014-2019)
10.4 Rubraca Sales Growth and Price
10.4.1 Global Rubraca Sales Growth (2014-2019)
10.4.2 Global Rubraca Price (2014-2019)
10.5 Talzenna Sales Growth and Price
10.5.1 Global Talzenna Sales Growth (2014-2019)
10.5.2 Global Talzenna Price (2014-2019)
10.6 Other Sales Growth and Price
10.6.1 Global Other Sales Growth (2014-2019)
10.6.2 Global Other Price (2014-2019)
11 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Segment by Application
11.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Application (2014-2019)
11.2 Ovarian Cancer Sales Growth (2014-2019)
11.3 Breast Cancer Sales Growth (2014-2019)
11.4 Other Sales Growth (2014-2019)
12 PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Forecast (2019-2024)
12.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales, Revenue and Growth Rate (2019-2024)
12.2 PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Forecast by Regions (2019-2024)
12.2.1 North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Forecast (2019-2024)
12.2.2 Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Forecast (2019-2024)
12.2.3 Asia-Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Forecast (2019-2024)
12.2.4 South America PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Forecast (2019-2024)
12.2.5 Middle East and Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Forecast (2019-2024)
12.3 PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Forecast by Type (2019-2024)
12.3.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Forecast by Type (2019-2024)
12.3.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Share Forecast by Type (2019-2024)
12.4 PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Forecast by Application (2019-2024)
12.4.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Forecast by Application (2019-2024)
12.4.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Share Forecast by Application (2019-2024)
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.1.3 Marketing Channel Future Trend
13.2 Distributors, Traders and Dealers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Data Source
Figure PARP (Poly ADP-Ribose Polymerase) Inhibitor Picture
Table Product Specifications of PARP (Poly ADP-Ribose Polymerase) Inhibitor
Figure Global Sales Market Share of PARP (Poly ADP-Ribose Polymerase) Inhibitor by Types in 2018
Table PARP (Poly ADP-Ribose Polymerase) Inhibitor Types for Major Manufacturers
Figure Lynparza Picture
Figure Zejula Picture
Figure Rubraca Picture
Figure Talzenna Picture
Figure Other Picture
Figure PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Applications in 2018
Figure Ovarian Cancer Picture
Figure Breast Cancer Picture
Figure Other Picture
Figure United States PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue (Value) and Growth Rate (2014-2024)
Figure Canada PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue (Value) and Growth Rate (2014-2024)
Figure Mexico PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue (Value) and Growth Rate (2014-2024)
Figure Germany PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue (Value) and Growth Rate (2014-2024)
Figure France PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue (Value) and Growth Rate (2014-2024)
Figure UK PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue (Value) and Growth Rate (2014-2024)
Figure Russia PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue (Value) and Growth Rate (2014-2024)
Figure Italy PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue (Value) and Growth Rate (2014-2024)
Figure China PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue (Value) and Growth Rate (2014-2024)
Figure Japan PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue (Value) and Growth Rate (2014-2024)
Figure Korea PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue (Value) and Growth Rate (2014-2024)
Figure India PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue (Value) and Growth Rate (2014-2024)
Figure Southeast Asia PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue (Value) and Growth Rate (2014-2024)
Figure Brazil PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue (Value) and Growth Rate (2014-2024)
Figure Egypt PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue (Value) and Growth Rate (2014-2024)
Figure Saudi Arabia PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue (Value) and Growth Rate (2014-2024)
Figure South Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue (Value) and Growth Rate (2014-2024)
Figure Nigeria PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue (Value) and Growth Rate (2014-2024)
Table AstraZeneca Basic Information, Manufacturing Base and Competitors
Table AstraZeneca PARP (Poly ADP-Ribose Polymerase) Inhibitor Type and Applications
Table AstraZeneca PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
Table Tesaro Basic Information, Manufacturing Base and Competitors
Table Tesaro PARP (Poly ADP-Ribose Polymerase) Inhibitor Type and Applications
Table Tesaro PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
Table Merck & Co Basic Information, Manufacturing Base and Competitors
Table Merck & Co PARP (Poly ADP-Ribose Polymerase) Inhibitor Type and Applications
Table Merck & Co PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
Table Clovis Oncology Basic Information, Manufacturing Base and Competitors
Table Clovis Oncology PARP (Poly ADP-Ribose Polymerase) Inhibitor Type and Applications
Table Clovis Oncology PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
Table Pfizer Basic Information, Manufacturing Base and Competitors
Table Pfizer PARP (Poly ADP-Ribose Polymerase) Inhibitor Type and Applications
Table Pfizer PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
Table Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Manufacturer (2017-2018)
Figure Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Manufacturer in 2017
Figure Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Manufacturer in 2018
Table Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Manufacturer (2017-2018)
Figure Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Manufacturer in 2017
Figure Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Manufacturer in 2018
Figure Top 3 PARP (Poly ADP-Ribose Polymerase) Inhibitor Manufacturer (Revenue) Market Share in 2018
Figure Top 6 PARP (Poly ADP-Ribose Polymerase) Inhibitor Manufacturer (Revenue) Market Share in 2018
Figure Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales and Growth Rate (2014-2019)
Figure Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue and Growth Rate (2014-2019)
Table Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Regions (2014-2019)
Table Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Regions (2014-2019)
Table Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Regions (2014-2019)
Figure Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Regions (2014-2019)
Figure Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Regions in 2018
Figure North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales and Growth Rate (2014-2019)
Figure Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales and Growth Rate (2014-2019)
Figure Asia-Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales and Growth Rate (2014-2019)
Figure South America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales and Growth Rate (2014-2019)
Figure Middle East and Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales and Growth Rate (2014-2019)
Figure North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue and Growth Rate (2014-2019)
Table North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Countries (2014-2019)
Table North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Countries (2014-2019)
Figure North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Countries (2014-2019)
Figure North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Countries in 2018
Table North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Countries (2014-2019)
Table North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Countries (2014-2019)
Figure North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Countries (2014-2019)
Figure North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Countries in 2018
Figure United States PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales and Growth Rate (2014-2019)
Figure Canada PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales and Growth Rate (2014-2019)
Figure Mexico PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales and Growth Rate (2014-2019)
Figure Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue and Growth Rate (2014-2019)
Table Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Countries (2014-2019)
Table Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Countries (2014-2019)
Table Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Countries (2014-2019)
Figure Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Countries (2014-2019)
Figure Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Countries in 2018
Figure Germany PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales and Growth Rate (2014-2019)
Figure UK PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales and Growth Rate (2014-2019)
Figure France PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales and Growth Rate (2014-2019)
Figure Russia PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales and Growth Rate (2014-2019)
Figure Italy PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales and Growth Rate (2014-2019)
Figure Asia-Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue and Growth Rate (2014-2019)
Table Asia-Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Countries (2014-2019)
Table Asia-Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Countries (2014-2019)
Figure Asia-Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Countries 2018
Table Asia-Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Countries (2014-2019)
Figure Asia-Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Countries 2018
Figure China PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales and Growth Rate (2014-2019)
Figure Japan PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales and Growth Rate (2014-2019)
Figure Korea PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales and Growth Rate (2014-2019)
Figure India PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales and Growth Rate (2014-2019)
Figure Southeast Asia PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales and Growth Rate (2014-2019)
Figure South America PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue and Growth Rate (2014-2019)
Table South America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Countries (2014-2019)
Table South America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Countries (2014-2019)
Figure South America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Countries in 2018
Table South America PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Countries (2014-2019)
Table South America PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Countries (2014-2019)
Figure South America PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Countries in 2018
Figure Brazil PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales and Growth Rate (2014-2019)
Figure Argentina PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales and Growth Rate (2014-2019)
Figure Colombia PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales and Growth Rate (2014-2019)
Figure Middle East and Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue and Growth Rate (2014-2019)
Table Middle East and Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Countries (2014-2019)
Table Middle East and Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Countries (2014-2019)
Figure Middle East and Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Countries in 2018
Table Middle East and Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Countries (2014-2019)
Table Middle East and Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Countries (2014-2019)
Figure Middle East and Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Countries (2014-2019)
Figure Middle East and Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Countries in 2018
Figure Saudi Arabia PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales and Growth Rate (2014-2019)
Figure UAE PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales and Growth Rate (2014-2019)
Figure Egypt PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales and Growth Rate (2014-2019)
Figure Nigeria PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales and Growth Rate (2014-2019)
Figure South Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales and Growth Rate (2014-2019)
Table Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Type (2014-2019)
Table Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Share by Type (2014-2019)
Table Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Type (2014-2019)
Table Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Share by Type (2014-2019)
Figure Global Lynparza Sales Growth (2014-2019)
Figure Global Lynparza Price (2014-2019)
Figure Global Zejula Sales Growth (2014-2019)
Figure Global Zejula Price (2014-2019)
Figure Global Rubraca Sales Growth (2014-2019)
Figure Global Rubraca Price (2014-2019)
Figure Global Talzenna Sales Growth (2014-2019)
Figure Global Talzenna Price (2014-2019)
Figure Global Other Sales Growth (2014-2019)
Figure Global Other Price (2014-2019)
Table Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Application (2014-2019)
Table Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Share by Application (2014-2019)
Figure Global Breast Cancer Sales Growth (2014-2019)
Figure Global Other Sales Growth (2014-2019)
Figure Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales, Revenue and Growth Rate (2019-2024)
Table Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Forecast by Regions (2019-2024)
Table Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Share Forecast by Regions (2019-2024)
Figure North America Sales PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Forecast (2019-2024)
Figure Europe Sales PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Forecast (2019-2024)
Figure Asia-Pacific Sales PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Forecast (2019-2024)
Figure South America Sales PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Forecast (2019-2024)
Figure Middle East and Africa Sales PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Forecast (2019-2024)
Table Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Forecast by Type (2019-2024)
Table Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Share Forecast by Type (2019-2024)
Table Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Forecast by Application (2019-2024)
Table Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Share Forecast by Application (2019-2024)
Table Distributors/Traders/ Dealers List
世界のPARP（ポリADPリボースポリメラーゼ）阻害剤市場：市場規模・現状・予測 PARP means poly (adenosine diphosphate [ADP] -ribose) polymerase. It is a family of 17 enzymes that combine several (poly) units of ADP-ribose in a chain (the PAR chain) and transfers them to the target proteins. This helps to restore DNA when it is damaged. DNA can be damaged by many factors, inclu…- 乳がんPARP阻害剤の世界市場予測 2024年：企業別、地域別、種類・用途別（～2024） Scope of the Report: The global PARP Inhibitors for Breast Cancer market is valued at xx million USD in 2018 and is expected to reach xx million USD by the end of 2024, growing at a CAGR of xx% between 2019 and 2024. The Asia-Pacific will occupy for more market share in following years, especially i…
- 乳癌用標的薬の世界市場予測 2024年：企業別、地域別、種類・用途別（～2024） Scope of the Report: The global Targeted Drugs for Breast Cancer market is valued at xx million USD in 2018 and is expected to reach xx million USD by the end of 2024, growing at a CAGR of xx% between 2019 and 2024. The Asia-Pacific will occupy for more market share in following years, especially in…
- 乳がんCDK4 / 6阻害剤の世界市場予測 2024年：企業別、地域別、種類・用途別（～2024） Scope of the Report: The global CDK4/6 Inhibitors for Breast Cancer market is valued at xx million USD in 2018 and is expected to reach xx million USD by the end of 2024, growing at a CAGR of xx% between 2019 and 2024. The Asia-Pacific will occupy for more market share in following years, especially…
- 乳癌用HER-2標的薬の世界市場予測 2024年：企業別、地域別、種類・用途別（～2024） Scope of the Report: The global HER-2 Targeted Drugs for Breast Cancer market is valued at xx million USD in 2018 and is expected to reach xx million USD by the end of 2024, growing at a CAGR of xx% between 2019 and 2024. The Asia-Pacific will occupy for more market share in following years, especia…